IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,
  Defendants.

⸻ 

PLAINTIFF’S FIRST SET OF REQUESTS FOR ADMISSION TO DEFENDANT PALANTIR TECHNOLOGIES INC.

Preamble (Relevance Statement)
Plaintiff Kellyn Clay alleges that Palantir Technologies engaged in retaliatory surveillance and coordination with private and public entities to suppress Plaintiff’s expressive activity, including by facilitating medical sabotage that impaired Plaintiff’s ability to speak. These requests for admission are designed to establish Palantir’s knowledge of Plaintiff’s speech activity, its coordination with supplement distributors and government agencies, and its role in shaping or enabling retaliatory measures.

⸻

Requests for Admission
	1.	Admit that Palantir has monitored or analyzed Plaintiff’s expressive activities, including speech, writing, or online posting.
	2.	Admit that Palantir has provided surveillance or analytic services to agencies or contractors with authority over health or supplement distribution.
	3.	Admit that Palantir has communicated with Amazon regarding supplement distribution, labeling, or consumer safety.
	4.	Admit that Palantir has communicated with the Minnesota Department of Health regarding surveillance, data integration, or supplement-related programs.
	5.	Admit that Palantir possessed or had access to health-related or biometric data concerning Plaintiff.
	6.	Admit that Palantir shared or analyzed health-related data in a manner that could be used to identify vulnerabilities affecting Plaintiff’s ability to speak.
	7.	Admit that Palantir has engaged in contracts or collaborations involving retaliation against individuals identified as anomalies or dissidents.
	8.	Admit that Palantir was aware that combined or mislabeled administration of supplements, including vitamin D3, could impair speech capacity through calcification or related mechanisms.
	9.	Admit that Palantir communicated with any government or private entity concerning Plaintiff’s speech activity and potential methods of suppression.
	10.	Admit that Palantir’s actions, including surveillance and coordination, contributed to adverse medical interventions directed at Plaintiff.

